The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zueva I.B.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
St. Petersburg clinical scientific and practical center for specialized types of medical care, Saint-Petersburg, Russia

Krivonosov D.S.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
Almazov National medical research center, Saint-Petersburg, Russia

Buch A.V.

Almazov National medical research center, Saint-Petersburg, Russia

Kim Yu.V.

Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia

Cognitive impairment in patients with metabolic syndrome. The current treatment possibilities

Authors:

Zueva I.B., Krivonosov D.S., Buch A.V., Kim Yu.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5): 18‑22

DOI: 10.17116/jnevro20181185118

Read: 1065 times

Download PDF (RU)
Contact the author
Table of contents

COGNITIVE IMPAIRMENT IN PATIENTS WITH METABOLIC SYNDROME. THE CURRENT TREATMENT POSSIBILITIES
COGNITIVE IMPAIRMENT IN PATIENTS WITH METABOLIC SYNDROME. THE CURRENT TREATMENT POSSIBILITIES

To cite this article:

Zueva IB, Krivonosov DS, Buch AV, Kim YuV. Cognitive impairment in patients with metabolic syndrome. The current treatment possibilities. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5):18‑22. (In Russ.)
https://doi.org/10.17116/jnevro20181185118

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Improving the effe­ctiveness of treatment of patients with post-stroke apha­sia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):22-28
Vita­min B12 defi­ciency in the elde­rly and its asso­ciations with geriatric syndromes. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):41-47
Diagnosis of neuroinfections in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11-2):51-59
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
The role of drug Cyto­flavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170
Inte­rnational multicenter randomized double-blind placebo-controlled study asse­ssing the effi­cacy and safety of sequential therapy with Mexi­dol and Mexi­dol FORTE 250 in patients with chro­nic brain ischemia (MEMO): suba­nalysis in patients with arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2024;(10):72-83
Reso­lution of the expert council «Possibilities of neuroprotective therapy in patients with arte­rial hype­rtension and cognitive diso­rders». Russian Journal of Preventive Medi­cine. 2024;(11):85-93
Problems of regu­lar medi­cal check-up orga­nization of young males aged 15—17 years with cardiometabolic diseases. Russian Journal of Preventive Medi­cine. 2024;(12):81-87
Differentiated approach to cognitive reha­bilitation of patients after stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):5-11
Abstract:

Objective. To study the effect of therapy with cytoflavin on cognitive function in patients with metabolic syndrome (MS). Material and methods. The randomized controlled open study included 156 patients with MS. The mean age was 41.27±5.16 years. The duration of observation was 16 weeks. The main group of patients (n=78) received cytoflavin in the dose of 2 tablets 2 times a day. Patients in the control group (n=78) received basic therapy. All patients underwent neuropsychological testing at baseline, after 2 months and at the end of the study. Cognitive evoked potentials (Р300) were recorded to assess cognitive functions. The levels of plasma glucose and lipid profile were measured. Results. Cytoflavin improved cognitive functions. Two months after treatment, the results of neuropsychological testing and electrophysiological study were better in the main group compared to the control group.

Keywords:

metabolic syndrome
cognitive disorders
cytoflavin

Authors:

Zueva I.B.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
St. Petersburg clinical scientific and practical center for specialized types of medical care, Saint-Petersburg, Russia

Krivonosov D.S.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
Almazov National medical research center, Saint-Petersburg, Russia

Buch A.V.

Almazov National medical research center, Saint-Petersburg, Russia

Kim Yu.V.

Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia

Close metadata

References:

  1. Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in ageing populations: application to Alzheimer’s disease. Stat Med. 2000;19(11-12):1481-1493.
  2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-1132. https://doi.org/10.1016/j.jacc.2010.05.034
  3. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet. 2012;379:2291-2399. https://doi.org/10.1016/S0140-6736(12)60360-2
  4. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry. 2007;48:57-61. https://doi.org/10.1016/j.comppsych.2006.05.001
  5. Dahl AK, Hassing LB, Fransson EI, Gatz M, Reynolds CA, Pedersen NL. Body mass index across midlife and cognitive change in late life. Int J Obes. 2013;37:296-302. https://doi.org/10.1038/ijo.2012.37
  6. Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010;7:686-698. https://doi.org/10.1038/nrcardio.2010.161
  7. Koch M, Jensen MK. HDL-cholesterol and apolipoproteins in relation to dementia. Curr Opin Lipidol. 2016;27:76-87. https://doi.org/10.1097/MOL.0000000000000257
  8. Zueva IB, Vanaeva KI, Sanez EL, Piotrovskaya VR, Genikhovich EL, Kirillova VI, Shlyakhto EV. Association of cognitive function with cardiovascular risk factors in middle age. J Hypertension. 2011;17(5):432-441.(In Russ.)
  9. Efimova I, Efimova N, Lishmanov Y. Cerebral Blood Flow and Cognitive Function in Patients With Metabolic Syndrome: Effect of Antihypertensive Therapy. J Clin Hypertens (Greenwich). 2014;16(12):900-906. https://doi.org/10.1111/jch.12435
  10. Sitburana O, Ondo WG. Brain magnetic resonance imagimg in parkinsonian disorders. Parkinsonism and Related Disorders. 2009;15:165-174. https://doi.org/10.1016/j.parkreldis.2008.04.033
  11. Zueva IB, Moroshkina NV, Barantsevich ER, Trufanov GE. Magnetic resonance spectroscopy in evaluation of cognitive functions in patients with metabolic syndrome. J Hypertension. 2013;19(1):51-58. (In Russ.)
  12. Bakker FC, Klijn CJ, Jennekens-Schinkel A, van der Tweel I, van der Grond J, van Huffelen AC, Tulleken CA, Kappelle LJ. Cognitive impairment is related to cerebral lactate in patients with carotid artery occlusion and ipsilateral transient ischemic attacks. Stroke. 2003;34(6):1419-1424. https://doi.org/10.1161/01.STR.0000069725.09499.14
  13. Klijn CJM, Kappelle LJ, van der Grond J, Algra A, Tulleken CAF, van Gijn J. Magnetic resonance techniques for the identification of patients with symptomatic carotid artery occlusion at high risk of cerebral ischemic events. Stroke. 2000;31:3001-3007.
  14. Belova LA, Mashin VV, Kolotik-Kamenev OYu, Belova NV, Angelo Scuderi, Pier Luigi Antignani. Effect of cytoflavin on the clinical and autonomic-psychological manifestations of hypertensive disease. Therapeutic archive. 2016;88(5):55-61. (In Russ.) https://doi.org/10.17116/terarkh201688555-61
  15. Muratov FH, Shermuhamedova FK, Batotsyrenov BV, Kharitonova TV. Multimodal action of cytoflavin in acute cerebral stroke, developed on the background of metabolic syndrome. Journal of neurology and psychiatry im. S.S. Korsakov. 2016;116(12):44-47. (In Russ.) https://doi.org/10.17116/jnevro201611612144-47
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.